Monoclonal antibodies (mAbs) targeting amyloid beta (Aβ) have demonstrated efficacy in treating Alzheimer’s Disease (AD). However, amyloid-related imaging abnormalities (ARIA) are a common adverse event and remain a challenge for anti-Aβ drug development. The mechanisms underlying ARIA are not well understood, but are hypothesized to be related to cerebrovascular amyloid deposits called Cerebral Amyloid Angiopathy (CAA). Here, we have expanded an existing quantitative systems pharmacology (QSP) model of AD1, describing Aβ biology and the activity of anti-Aβ mAbs, to enable hypothesis testing of potential ARIA mechanisms and prediction of ARIA incidence for APOEε4 carrier and non-carrier patients from <em>in vitro </em>CAA binding data.